Innoviva Inc (INVA)
Operating profit margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Operating income | US$ in thousands | 229,367 | 176,709 | 209,991 | 375,103 | 321,123 |
Revenue | US$ in thousands | 358,711 | 310,463 | 331,339 | 391,866 | 336,794 |
Operating profit margin | 63.94% | 56.92% | 63.38% | 95.72% | 95.35% |
December 31, 2024 calculation
Operating profit margin = Operating income ÷ Revenue
= $229,367K ÷ $358,711K
= 63.94%
Innoviva Inc's operating profit margin has demonstrated a relatively strong performance over the years, showing a consistent level above 50%. The margin has shown a downward trend from 95.35% in 2020 to 56.92% in 2023, with a slight increase to 63.94% in 2024. The company's ability to generate profits from its core operations has remained notably high, although there was a slight decline in profitability in 2023. It is important for Innoviva Inc to closely monitor and manage its operating expenses to ensure sustained profitability in the future.
Peer comparison
Dec 31, 2024
Company name
Symbol
Operating profit margin
Innoviva Inc
INVA
63.94%
Abbott Laboratories
ABT
16.27%
AbbVie Inc
ABBV
16.22%
ACADIA Pharmaceuticals Inc
ACAD
24.10%
Alkermes Plc
ALKS
27.02%
Amphastar P
AMPH
28.06%
ANI Pharmaceuticals Inc
ANIP
0.10%
Arcus Biosciences Inc
RCUS
-127.91%
Biomarin Pharmaceutical Inc
BMRN
17.02%
Bristol-Myers Squibb Company
BMY
-25.99%
Catalyst Pharmaceuticals Inc
CPRX
39.68%